Clinical Trial: SWOG MM1YA-CTG01

SWOG MM1YA-CTG01

Status: New, Open

A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial

(See required screening study MYELOMATCH)